Press Releases

InteRNA Technologies Receives Regulatory Approval for Initiation of Phase I Clinical Trial of INT-1B3 in Patients with Advanced Solid Tumors

May 06, 2020
InteRNA Technologies Receives Regulatory Approval for Initiation of Phase I Clinical Trial of INT-1B3 in Patients with Advanced...
Read more
InteRNA Technologies Receives Regulatory Approval for Initiation of Phase I Clinical Trial of INT-1B3 in Patients with Advanced Solid Tumors

ISA Pharmaceuticals announces CervISA publication

March 19, 2020
Synergy between Synthetic Long Peptides (SLP®) immunotherapeutics and standard chemotherapy in late stage cancer including mean...
Read more
ISA Pharmaceuticals announces CervISA publication

MIMETAS to launch Assay Ready product line for Organ-on-a-Chip

March 03, 2020
MIMETAS announces the first product release of her Assay Ready product line: OrganoPlate® Caco-2. Innovative in-vitro models r...
Read more
MIMETAS to launch Assay Ready product line for Organ-on-a-Chip

Sapreme Technologies in a 6.8 M€ EU Alliance

February 20, 2020
Sapreme Technologies in a 6.8 M€ EU Alliance to Develop an Oligonucleotide Delivery Platform Based on Its Proprietary Endosomal...
Read more
Sapreme Technologies in a 6.8 M€ EU Alliance

Macrophage Pharma Expands Executive Team with Chief Scientific Officer and Chief Technology Officer

January 09, 2020
Key hires enhance management for next development phase
Read more
Macrophage Pharma Expands Executive Team with Chief Scientific Officer and Chief Technology Officer

Aglaia Oncology Funds and Sinzer - Grant Thornton Launch Dedicated Life Sciences Impact Measuring and Reporting Suite

December 19, 2019
• Enables visibility for investors of social impact realized by their investments • Suite demonstrates value beyond financial...
Read more
Aglaia Oncology Funds and Sinzer - Grant Thornton Launch Dedicated Life Sciences Impact Measuring and Reporting Suite

InteRNA presents data on drug formulation and mode of action of lead oncology development candidate INT-1B3 at the 15th annual OTS meeting

October 31, 2019
InteRNA presents data on drug formulation and mode of action of lead oncology development candidate INT-1B3 at the 15th annual...
Read more
InteRNA presents data on drug formulation and mode of action of lead oncology development candidate INT-1B3 at the 15th annual OTS meeting

Macrophage Pharma Appoints Dr Anker Lundemose to the Board of Directors

September 26, 2019
Macrophage Pharma Limited has appointed Dr. Anker Lundemose as independent non-executive director.
Read more
Macrophage Pharma Appoints Dr Anker Lundemose to the Board of Directors

Macrophage Pharma appoints Dr Søren Bregenholt as Chief Executive Officer

September 03, 2019
Macrophage Pharma Limited ('MPL') announced today that it has appointed Dr Søren Bregenholt as Chief Executive Officer....
Read more
Macrophage Pharma appoints Dr Søren Bregenholt as Chief Executive Officer

Cristal Therapeutics appoints Dr Werner Cautreels as a new Director and Board Chairman and Andre Verwei as Chief Financial Officer

August 01, 2019
Maastricht, The Netherlands, 1st August 2019 - Cristal Therapeutics, a Phase 2 clinical stage pharmaceutical company developing...
Read more
Cristal Therapeutics appoints Dr Werner Cautreels as a new Director and Board Chairman and Andre Verwei as Chief Financial Officer

Modra Pharmaceuticals Announces First Patients Treated in Phase IIb Metastatic Prostate Cancer Trial

August 01, 2019
AMSTERDAM--(BUSINESS WIRE)--Modra Pharmaceuticals B.V. ("Modra") today announced the start of patient treatment in its Phase II...
Read more
Modra Pharmaceuticals Announces First Patients Treated in Phase IIb Metastatic Prostate Cancer Trial

Home > Press Releases

© 2020 Aglaia Oncology Funds | Privacy | Sitemap
Aglaia Oncology Funds